Merck Rewards Pioneering Researchers
Grant for Oncology Innovation Initiative grants €1 Mio
29-Sep-2015
- Germany
- Dr Roberto Chiarle, University of Turin, Italy, for his proposal to elucidate the molecular mechanisms underlying relapse in a subset of patients with non-small cell lung cancer, following anaplastic lymphoma kinase (ALK)-targeted tyrosinekinase inhibitor (TKI) therapy. Around half of patients treated with ALK-TKI therapy will relapse without explanation, meaning they are not able to benefit from additional lines of targeted therapy.
- Dr Josep Maria Piulats Rodriguez, Catalan Institute of Oncology, Spain, for his proposal to explore immunogenic mutations as a therapeutic target, and to demonstrate the potential for personalized cancer-specific vaccines to generate T-cell responses in human tumors.
- Dr Rodrigo Dienstmann, Vall d'Hebron Institute of Oncology, Spain, for his proposal to analyze clinical and gene expression data, and translating the findings to inform the design of early clinical trials into therapies that target intracellular signals on which colorectal cancers depend.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.